Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viemed HealthcareVMD +1.43%93 ROE % is 7.24% as of Mar. 2026, which is 32% below its 10-year median of 10.64. GuruFocus rates VMD with a GF Score™ of 93/100 and a GF Value™ of $10.94 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Viemed Healthcare ranks better than 76.6% on this metric.
The historical rank and industry rank for Viemed Healthcare's ROE % or its related term are showing as below:
VMD'
s ROE % Range Over the Past 10 Years
Min: 6.48 Med: 10.64 Max: 50.29
Current: 10.74
During the past 10 years, Viemed Healthcare's highest ROE % was 50.29%. The lowest was 6.48%. And the median was 10.64%.
VMD's ROE % is ranked better than 76.6% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.54
vs VMD: 10.74
Viemed Healthcare (NAS:VMD) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Viemed Healthcare ROE % Related Terms
Viemed Healthcare ROE % Historical Data
* Premium members only.
The historical data trend for Viemed Healthcare's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Viemed Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viemed Healthcare ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viemed Healthcare's ROE % distribution charts can be found below:
* The bar in red indicates where Viemed Healthcare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Viemed Healthcare (VMD) has a ROE % of 7.24% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Viemed Healthcare and its competitors. This is 32% below median its historical median of 10.64. Over the past decade, Viemed Healthcare's ROE % has ranged from 6.48 to 50.29. According to the industry distribution chart, Viemed Healthcare ranks #187 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 23.4%.
Is Viemed Healthcare's ROE % too high?
Viemed Healthcare's current ROE % of 7.24% is 32% below median its 10-year median of 10.64. Over the past 10 years, this metric has ranged from a low of 6.48 to a high of 50.29. The Medical Devices & Instruments industry median ROE % is 2.54. Viemed Healthcare's value of 7.24% is 185% above this industry median. Based on the distribution chart, Viemed Healthcare ranks #187 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Viemed Healthcare has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viemed Healthcare's ROE % compare to DCTH and VREX?
According to the Medical Devices & Instruments industry distribution chart, Viemed Healthcare ranks #187 out of 799 companies for ROE %. This places Viemed Healthcare in the top 23% of its industry — outperforming the majority of peers. The industry median ROE % is 2.54. Viemed Healthcare's value of 7.24% is 185% above this benchmark. Historically, Viemed Healthcare's own ROE % has ranged from 6.48 to 50.29 over the past decade. While the company's 10-year median is 10.64 vs. the industry median of 2.54, Viemed Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.54, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viemed Healthcare's current ROE % of 7.24% is 185% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Viemed Healthcare and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viemed Healthcare's current ROE % is 7.24%, which is 32% below median its own 10-year median of 10.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viemed Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Viemed Healthcare (VMD) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.94, compared to a current price of $12.11 — trading 10.7% above its estimated fair value. The current ROE % is 7.24%, which is 32% below median its 10-year median of 10.64 and 185% above the Medical Devices & Instruments industry median of 2.54. Viemed Healthcare's overall GF Score™ is 93/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Viemed Healthcare (VMD), the current ROE % is 7.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viemed Healthcare (VMD) Overvalued in 2026?
Based on GuruFocus' analysis, Viemed Healthcare stock appears to be overvalued.
The current stock price of $12.11 is trading 10.7% above its estimated GF Value™ of $10.94.
GuruFocus considers Viemed Healthcare to be Modestly Overvalued.
Key valuation signals for VMD:
ROE %: 7.24% (32% below median its 10-year median of 10.64)
GF Value™: $10.94 vs. price of $12.11 (10.7% above fair value)
Industry Position: 185% above the Medical Devices & Instruments median (#187 of 799)
No single metric tells the full story. See the VMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
93GF Score
Get the complete analysis for VMD
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMD has been successfully added to your 
